Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154035 | 1.00 | CYP2C9 (0.43) | CYP2C9PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL13154043 | 1.00 | CYP2C9 (0.43) | CYP2C9PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL15996559 | 0.84 | CYP2C9 (0.45) | CYP2C9PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL13932943 | 0.84 | CYP2C9 (0.45) | CYP2C9PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL22267166 | 0.84 | CYP2C9 (0.45) | CYP2C9PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL13122862 | 0.83 | CYP2C9 (0.43) | CYP2C9PSMB5MEN1KMT2AFAAH | |
| SCHEMBL4195960 | 0.83 | CYP2C9 (0.43) | CYP2C9PSMB5ALDH1A1NPSR1 | |
| SCHEMBL8533308 | 0.83 | CYP2C9 (0.43) | CYP2C9PSMB5MEN1KMT2AFAAH | |
| SCHEMBL13122868 | 0.83 | CYP2C9 (0.43) | CYP2C9PSMB5MEN1KMT2AFAAH | |
| SCHEMBL8827985 | 0.83 | CYP2C9 (0.43) | CYP2C9PSMB5MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120149710-A1 | SORTASE A INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-06-14 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149710-A1 | SORTASE A INHIBITORS | STS, ENGASE, SPR | CYP2C9 1965/4885PSMB5 3847/4885MEN1 3994/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | CYP2C9 262/4885PSMB5 1245/4885MEN1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.